InsidersTradesSigma
Follow the IMMUNE PHARMACEUTICALS INC stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €222.9m. The latest transaction was reported on 26 January 2016 (Acquisition). Among the most active insiders: Teper Daniel Gedeon. Every trade is accessible without an account.
Analysts rate IMMUNE PHARMACEUTICALS INC Strong Buy (bullish), based on 4 analysts. Average price target: US$8.61.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
IMMUNE PHARMACEUTICALS INC is a biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. It is listed on NASDAQ under the ticker IMNP.